Clarient, Inc. (NASDAQ:CLRT) skyrocketed
33.02% to $4.97. Last week, GE Healthcare, a unit of GE, and Clarient, Inc.
announced that they have entered into a definitive agreement for GE Healthcare
to acquire Clarient. A subsidiary of GE will commence a tender offer for all
outstanding common and preferred shares of Clarient at $5.00 per common share
and $20.00 per preferred share, in each case payable in cash.
Over the
past 52-week, the stock traded within the range of $1.88-$5 and is up more than
17% year-to-date. The stock went up more
than 5% year-to-date.
Medivation,
Inc. (NASDAQ:MDVN) dropped 4.18% to $11.22. Medivation, Inc. is a
biopharmaceutical company. The Company focuses on the development of small
molecule drugs to treat serious diseases.
The stock is down more than 70% year-to-date.
Cell Therapeutics, Inc. (NASDAQ:CTIC) went up 5.94%
to $0.410. Last week, the company announced that it has entered into an
agreement to sell $21.0 million of shares of its Series 7 Preferred Stock and
warrants to purchase shares of its common stock in a registered offering to
four institutional investors.
Each
share of Series 7 Preferred Stock is convertible at the option of the holder,
at any time during its existence, into approximately 2,703 shares of common
stock at a conversion price of $0.37 per share of common stock, for a total of
56,756,757 common shares.
Over the
past 52-week, the stock had traded within the range of $0.12-$1.40.
MannKind Corporation (NASDAQ:MNKD) jumped
3.83% to close at $6.50. Last week, the company announced the first patient has
been dosed in a phase 2 clinical trial of the investigational cancer vaccine
MKC1106-MT.
At Friday`s
closing market price, the market capitalization of the company stands at $857.18
million.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today. For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
